Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar 11;17(3):295-300.
doi: 10.1016/j.chom.2015.02.012.

Influenza vaccines: challenges and solutions

Katherine Houser  1 , Kanta Subbarao  2
Affiliations
Review

Influenza vaccines: challenges and solutions

Katherine Houser et al. Cell Host Microbe. .

Abstract

Vaccination is the best method for the prevention and control of influenza. Vaccination can reduce illness and lessen severity of infection. This review focuses on how currently licensed influenza vaccines are generated in the U.S., why the biology of influenza poses vaccine challenges, and vaccine approaches on the horizon that address these challenges.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Stages of the viral life cycle and vaccine targets
Many stages of viral infection can be targeted by vaccines; the targets of the vaccines described in this review are indicated. Vaccines that elicit an immune response that blocks a stage in the viral life cycle are shown in red, while vaccines that activate a specific host immune response are shown in green. Abbreviations: IIV: inactivated influenza vaccine; LAIV: live attenuated influenza vaccine; COBRA: computationally optimized broadly reactive antigen; HA: hemagglutinin; ADCC: antibody dependent cell cytotoxicity
See this image and copyright information in PMC

References

    1. Antrobus RD, Berthoud TK, Mullarkey CE, Hoschler K, Coughlan L, Zambon M, Hill AV, Gilbert SC. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. Molecular therapy : the journal of the American Society of Gene Therapy. 2014;22:233–238. - PMC - PubMed
    1. Antrobus RD, Lillie PJ, Berthoud TK, Spencer AJ, McLaren JE, Ladell K, Lambe T, Milicic A, Price DA, Hill AV, et al. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PloS one. 2012;7:e48322. - PMC - PubMed
    1. Babu TM, LM, Fitzgerald T, Luke C, Sangster MY, Jin H, Topham D, Katz J, Treanor J, Subbarao K. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine. 2014 In Press. - PMC - PubMed
    1. Baz M, Luke CJ, Cheng X, Jin H, Subbarao K. H5N1 vaccines in humans. Virus Res. 2013;178:78–98. - PMC - PubMed
    1. Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011;30:1081–1085. - PubMed

Publication types

MeSH terms